The raw material arrives alive. A patient's white blood cells are collected, shipped to a manufacturing site, genetically reprogrammed to recognize cancer, expanded, inspected, frozen and sent back for a one-time infusion. The route is less like filling a prescription than running a relay race in which hospitals, couriers, laboratories and regulators cannot drop the baton. This is the business Legend Biotech chose.
Its defining medicine, CARVYKTI, is a BCMA-directed CAR-T therapy for certain adults whose multiple myeloma has returned or stopped responding to treatment. It uses the patient's own T cells and equips them with a receptor carrying two BCMA-binding domains. Those engineered cells are intended to find and kill cells that display the target. In February 2022, CARVYKTI won its first U.S. approval. In April 2024, the label moved into an earlier treatment setting for eligible patients after at least one prior line of therapy.
By the end of 2025, more than 10,000 clinical and commercial patients had received it. In 2025, the medicine generated roughly $1.9 billion in worldwide net trade sales. By August 2026, it was available through 348 sites in 19 markets. For a company born in 2014, the trip from improvised project to global commercial network was unusually compressed.
A room with one good question
Legend began inside GenScript as the "Legend Project." The company's own history describes its first workspace as the size of a freight elevator. The researchers made nanobodies - compact, single-domain antibody fragments - and worked on extending their time in the body. By 2015, they had fixed on B-cell maturation antigen, or BCMA, as a target in multiple myeloma. Investigator-led trials began in China the following year.
The consequential moment came at the 2017 meeting of the American Society of Clinical Oncology. Early data caught the attention of Janssen Biotech, now part of Johnson & Johnson, and the companies signed a worldwide agreement that December to develop and commercialize ciltacabtagene autoleucel. Legend received $350 million upfront. More important than the cheque was the division of labor: the small science project gained the clinical, regulatory and commercial reach of a global pharmaceutical company.
“The treatment may happen once. The operation behind it must work every day.”The commercial paradox of personalized cell therapy
The customer is a network, not a shopper
The ultimate user is a person living with relapsed or refractory multiple myeloma. The practical customer, however, is a coordinated care system. Hematologists identify candidates. Authorized treatment centers manage collection, conditioning, infusion and follow-up. Payers assess a high-cost, one-time intervention. Manufacturing teams schedule a unique batch for a named patient. Johnson & Johnson and Legend coordinate market access, supply and commercialization.
That network solves two problems at once. The biological problem is a cancer that repeatedly finds ways around treatment. The operational problem is turning an individualized laboratory procedure into a reliable product. Legend's expanded Raritan, New Jersey operation can support treatment for as many as 10,000 patients a year. In early 2026, the company reported a 99 percent manufacturing success rate and said more than 95 percent of final-product orders were released on time. Those numbers are not decorative. A failed or late batch lands on a patient already waiting through serious disease.
Capacity is not the same as access. A center needs trained staff, collection slots, beds or outpatient space, and time to monitor for reactions after infusion. A patient may need bridging treatment while the cells are being prepared. Geography matters too: adding a market means more than securing regulatory clearance; it means qualifying sites and connecting them to the supply chain. Legend's push into community and outpatient settings is therefore a business expansion and a care redesign. The addressable market grows only when more eligible people can move through the complete process, not when another machine appears on a factory floor.
One medicine, several ways to earn
Legend is not a conventional drug seller with a warehouse of identical boxes. Most of its revenue is collaboration revenue generated by CARVYKTI sales under the Janssen agreement. The partners share development, production and commercialization economics. In 2025, Legend recorded $944.8 million in collaboration revenue and $84.1 million in license and other revenue, for total revenue of $1.0289 billion. The CARVYKTI franchise reached profitability for the full year, although Legend itself still reported an operating loss.
The model has a second leg: license the right science to a partner with complementary machinery. In 2023, Novartis agreed to pay $100 million upfront for worldwide rights to DLL3-targeted CAR-T programs including LB2102, plus as much as $1.01 billion in potential milestones and tiered royalties. Legend runs the current U.S. Phase 1 trial; Novartis is responsible for the wider development, manufacturing and commercialization work.
The platform hiding behind the product
CARVYKTI is autologous: the patient supplies the cells. Legend's pipeline now spreads across three manufacturing ideas. Allogeneic therapies start with donor cells and aim to create inventory that can be used for many patients. In vivo programs try to deliver genetic instructions directly into the body, turning immune cells into CAR-T cells without the familiar trip through an external factory. Each approach trades some personalization for the possibility of speed, availability and scale.
Autologous
Patient-derived cells. Proven commercially through CARVYKTI, but dependent on individualized manufacturing and scheduling.
Allogeneic
Donor-derived cells. Designed as a more available product, while still facing immune compatibility and durability questions.
In vivo
Genetic instructions delivered in the body. A bid to remove cell extraction and external engineering from the loop.
The early pipeline remains experimental. LB2501, an in vivo dual-targeting CD19/CD20 candidate, produced responses in a small Phase 1 group with relapsed or refractory B-cell non-Hodgkin lymphoma in 2026. LB2102, aimed at DLL3 in small-cell lung cancer and related neuroendocrine tumors, has supplied early human data. LUCAR-G39D represents the donor-derived approach in B-cell lymphoma. These are signals, not finished products. Small cohorts can open a door; larger, longer studies decide whether anyone gets to walk through it.
The useful distinction
Legend's approved business is CARVYKTI. Its allogeneic, solid-tumor and in vivo programs are investigational. Treating the pipeline as certain would erase the central risk of biotechnology.
Where Legend sits in the market
Within multiple myeloma, the clearest like-for-like competitor is Abecma, the other approved BCMA-directed autologous CAR-T in the United States. But patients and clinicians also weigh treatments that do not require bespoke cell manufacturing, including bispecific antibodies such as Tecvayli and Elrexfio, along with established drug combinations. Convenience, time to treatment, safety, prior therapies, health and access all shape the choice. Efficacy alone does not operate the clinic.
Legend's difference begins with the two BCMA-binding domains in the CARVYKTI construct, but it extends into the infrastructure built around them. The company handles work from discovery through manufacturing and commercialization, while Johnson & Johnson supplies global scale. That combination is difficult to copy quickly. It is also difficult to maintain: living medicines invite manufacturing variation, tight logistics and intensive safety monitoring. CAR-T products carry serious boxed warnings, and treatment belongs under experienced specialist care.
The company entered the second half of 2026 in transition. Ying Huang stepped down in July, and CARVYKTI business president Alan Bash became interim chief executive while the board searched for a permanent leader. Days later, Legend reported quarterly operating income of $57.7 million, total revenue of $387.5 million and about $965 million in cash and time deposits. It had also raised roughly $212 million in a June public offering. The balance sheet gives the pipeline time. It does not give the pipeline answers.
Legend's moat is part receptor design, part factory discipline and part calendar.Biology gets the attention. Coordination determines access.
The next constraint
Legend says its mission is "in pursuit of cures." Its stated values - Patient First, Innovation, One Team, Result Driven and Integrity - sound familiar on a corporate page. They become concrete on a manufacturing floor. Patient first means the right cells return to the right person. One team means a hospital and a release laboratory share a clock. Result driven means a batch cannot be almost ready.
The company now has more than 3,200 employees and facilities across the United States, China and Europe. It occupies an unusual middle ground: larger and more integrated than a research-stage biotech, narrower than the pharmaceutical groups it partners with. Its expertise is the entire cell-therapy chain - target discovery, genetic engineering, clinical trials, process development, quality, supply and market access.
That is why the most interesting question is no longer whether Legend can produce a striking clinical result. It has already converted one into an approved medicine and a sizable franchise. The question is whether it can make the system around personalized cell therapy feel less exceptional: fewer delays, more treatment sites, dependable batches, and eventually therapies that begin with donor cells or are programmed inside the body. The tiny room proved the idea. The global network has to prove the model.